Digestion最新文献

筛选
英文 中文
Factors Contributing to the Efficacy of Fecal Microbiota Transplantation for Diarrhea-Dominant Functional Bowel Disorders. 影响粪便微生物群移植治疗腹泻为主的功能性肠病疗效的因素。
IF 3 3区 医学
Digestion Pub Date : 2025-04-10 DOI: 10.1159/000545183
Tsuyoshi Yamane, Tatsuhiro Masaoka, Chiharu Ishii, Hiroaki Masuoka, Wataru Suda, Shunya Kurokawa, Taishiro Kishimoto, Yohei Mikami, Shinji Fukuda, Takanori Kanai
{"title":"Factors Contributing to the Efficacy of Fecal Microbiota Transplantation for Diarrhea-Dominant Functional Bowel Disorders.","authors":"Tsuyoshi Yamane, Tatsuhiro Masaoka, Chiharu Ishii, Hiroaki Masuoka, Wataru Suda, Shunya Kurokawa, Taishiro Kishimoto, Yohei Mikami, Shinji Fukuda, Takanori Kanai","doi":"10.1159/000545183","DOIUrl":"10.1159/000545183","url":null,"abstract":"<p><strong>Introduction: </strong>In cases of effective fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS), donor feces have been observed to be enriched in Bifidobacterium spp. Moreover, FMT for functional bowel disease can improve psychiatric symptoms. Although intestinal dysbiosis has received attention as one of the pathophysiologies of IBS, the efficacy of FMT for IBS has not yet been established. In this study, we performed a post hoc analysis of the efficacy of FMT, focusing on metabolites in donor feces.</p><p><strong>Methods: </strong>FMT was performed in 12 patients, 8 with refractory diarrhea-predominant IBS and 4 with functional diarrhea (FDr), who were refractory to medical therapy. The donors were family members within a second degree of kinship and differed for each transplant. Fecal characteristics were evaluated before and 12 weeks after transplantation using the Bristol stool scale (BS). BS scores of 3-5 at 12 weeks after transplantation were considered to indicate responders, while BS scores of 6 and 7 indicated nonresponders. Metagenomic and metabolomic analyses of all 12 donor fecal samples were performed to compare the responder and nonresponder groups.</p><p><strong>Results: </strong>Before transplantation, all patients had BS scores of 6-7, but 12 weeks after transplantation, 6 were considered responders and 6 were nonresponders. Metagenomic analysis showed that effective donor feces contained significantly higher levels of Prevotella than did the ineffective donor feces. Metabolomic analysis showed that effective donor feces contained significantly higher levels of propionate and butyrate and significantly lower lactate levels than did ineffective donor feces.</p><p><strong>Conclusion: </strong>Propionate-, butyrate-, or Prevotella-rich donor feces may contribute to successful FMT in patients with diarrhea-dominant functional gastrointestinal disorders.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between Microbiome Dysbiosis and Postoperative Disorders before and after Gastrectomy. 胃切除术前后微生物群失调与术后疾病的关系。
IF 3 3区 医学
Digestion Pub Date : 2025-04-09 DOI: 10.1159/000545678
Tsuyoshi Tanaka, Tadashi Fujii, Hideaki Takahashi, Kento Kuramitsu, Kohei Funasaka, Eizaburo Ohno, Shingo Akimoto, Masaya Nakauchi, Susumu Shibasaki, Ichiro Uyama, Yoshiki Hirooka, Koichi Suda, Takumi Tochio
{"title":"Association between Microbiome Dysbiosis and Postoperative Disorders before and after Gastrectomy.","authors":"Tsuyoshi Tanaka, Tadashi Fujii, Hideaki Takahashi, Kento Kuramitsu, Kohei Funasaka, Eizaburo Ohno, Shingo Akimoto, Masaya Nakauchi, Susumu Shibasaki, Ichiro Uyama, Yoshiki Hirooka, Koichi Suda, Takumi Tochio","doi":"10.1159/000545678","DOIUrl":"10.1159/000545678","url":null,"abstract":"<p><strong>Introduction: </strong>Gastrectomy considerably affects the gut microbiome; however, the association between dysbiosis and post-gastrectomy syndrome remains to be explored. This study prospectively explored fecal gut microbiota alterations following gastrectomy, investigating their potential association with weight loss.</p><p><strong>Methods: </strong>The gut microbiome of 21 patients with gastric cancer scheduled for gastrectomy in April-October 2022 was analyzed using 16S rRNA gene next-generation sequencing. Stool and blood samples were collected before and 3 months after gastrectomy. The microbiome profiles were compared to those of 85 healthy controls. Bacterial taxa demonstrating significant changes were determined using the linear discriminant analysis effect size algorithm and further analyzed for their relationship with weight loss in the gastrectomy cohort.</p><p><strong>Results: </strong>Postoperative complications (≥grade 2) were observed in 14.3% of patients. Postoperative weight loss was -10.9%, with the following breakdown: distal (-7.0%), total (-13.5%), and proximal (-14.0%) gastrectomy (p = 0.003). Microbiota analysis demonstrated a significant incline in the abundance of the Streptococcus salivarius group and a decline in Bacteroides uniformis in patients with gastric cancer compared to healthy controls. The S. salivarius group exhibited a further increase, while B. uniformis showed signs of recovery after gastrectomy. Additionally, 5α-reductase gene levels, reported to decrease as several cancers progress, were found to elevate post-surgery. Furthermore, patients experiencing greater weight loss showed a significant reduction in Faecalibacterium prausnitzii levels, while lower serum prealbumin and zinc levels were associated with the abundance of Escherichia coli.</p><p><strong>Conclusion: </strong>Gastrectomy significantly alters the gut microbiome. Supporting microbiome health with prebiotics may help alleviate postoperative issues and improve patients' quality of life.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KIF4A Facilitates Oxaliplatin Resistance and Stemness in Colon Cancer by Boosting Glucose Metabolism. KIF4A通过促进葡萄糖代谢促进结肠癌的奥沙利铂耐药和干细胞。
IF 3 3区 医学
Digestion Pub Date : 2025-03-27 DOI: 10.1159/000544914
Cheng Cai, Xia Zhang, Chenyang Ge, Shicheng Zhou, Zhekang Jin, Kangfu Dai, Nannan Dai, Xingxing Yu, Jianping Wang
{"title":"KIF4A Facilitates Oxaliplatin Resistance and Stemness in Colon Cancer by Boosting Glucose Metabolism.","authors":"Cheng Cai, Xia Zhang, Chenyang Ge, Shicheng Zhou, Zhekang Jin, Kangfu Dai, Nannan Dai, Xingxing Yu, Jianping Wang","doi":"10.1159/000544914","DOIUrl":"10.1159/000544914","url":null,"abstract":"<p><strong>Introduction: </strong>Colon cancer (CC) is a malignant tumor commonly found in the intestines with high incidence and mortality rates. Oxaliplatin (OXA) is a platinum-based chemotherapy drug widely used to treat CC. However, frequent drug resistance in patients results in suboptimal treatment outcomes. Though kinesin family member 4A (KIF4A) has been reported to be upregulated in various cancers and linked with poor prognosis in patients, its regulatory mechanism in cellular metabolism remains unclear.</p><p><strong>Methods: </strong>The human CC/OXA-resistant cell line (HCT116-R) was constructed. CCK-8 assay was employed to calculate the half-maximal inhibitory concentration (IC50) of CC cells. The level of cell stemness was assessed by cell sphere formation assay. The enrichment of KIF4A in signaling pathways of CC was analyzed through Gene Set Enrichment Analysis (GSEA). The bioinformatics analysis was applied to reveal the differential expression of KIF4A in CC and its correlation with genes related to stemness or glycolysis. The assessment of lactate in the supernatant was finished by utilizing the lactate detection kit. The oxidative phosphorylation and glycolysis levels in cells were measured by a Seahorse analyzer. The mRNA expression level of KIF4A was detected by quantitative real-time PCR. Furthermore, the Western blot (WB) was employed to determine the protein expression of glycolysis-related enzymes in cells. A mouse OXA-resistant CC xenograft tumor model was established, with changes in tumor volume and final weight recorded. TUNEL was utilized to detect the apoptosis level in tissues and immunohistochemistry to examine the distribution of KIF4A and ki-67 in tissues. The levels of stemness-related proteins in tissues were detected through WB.</p><p><strong>Results: </strong>KIF4A was upregulated in CC, exhibiting a positive association with OXA resistance. High expression of KIF4A promoted cancer cell survival and cancer stemness. In GSEA prediction, KIF4A in CC may be linked with the glycolysis pathway. Correspondingly, the expression of KIF4A in CC was positively correlated with the expression of glycolysis-related proteins. Tests for lactate content and glycolysis/oxidative phosphorylation levels revealed that knocking down KIF4A repressed glycolytic function in the drug-resistant strain but reinforced mitochondrial oxidative phosphorylation. Furthermore, KIF4A overexpression effectively boosted the OXA resistance and stemness of cells, which was reversed by glycolysis inhibitor. The mouse model validated the above results.</p><p><strong>Conclusion: </strong>KIF4A is significantly upregulated in CC to reinforce the glycolysis of cancer cells, thus facilitating cell stemness and resistance to OXA-based therapy.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations between Serum Insulin-Like Growth Factor-Related Molecules and Colorectal Cancer Risk by Tumor Location: A Nested Case-Control Study. 血清胰岛素样生长因子相关分子与结直肠癌风险与肿瘤位置的关系:一项巢式病例对照研究
IF 3 3区 医学
Digestion Pub Date : 2025-03-25 DOI: 10.1159/000545457
Yasushi Adachi, Masanori Nojima, Yingsong Lin, Yasushi Sasaki, Hiro-O Yamano, Hiroshi Nakase, Kenji Wakai, Mitsuru Mori, Akiko Tamakoshi
{"title":"Associations between Serum Insulin-Like Growth Factor-Related Molecules and Colorectal Cancer Risk by Tumor Location: A Nested Case-Control Study.","authors":"Yasushi Adachi, Masanori Nojima, Yingsong Lin, Yasushi Sasaki, Hiro-O Yamano, Hiroshi Nakase, Kenji Wakai, Mitsuru Mori, Akiko Tamakoshi","doi":"10.1159/000545457","DOIUrl":"10.1159/000545457","url":null,"abstract":"<p><strong>Introduction: </strong>The activity of the mitogen insulin-like growth factor (IGF) is controlled by IGF-binding protein (IGFBP). Colorectal cancers (CRCs) are heterogeneous, with left- and right-sided CRCs, showing different clinical and molecular characteristics. This case-control study, nested in the Japan Collaborative Cohort study, assessed associations between serum levels of IGF-related molecules and incidences of CRC by location.</p><p><strong>Methods: </strong>A baseline survey obtained serum samples from 39,242 participants. Subjects diagnosed with CRC during follow-up were regarded as cases. Conditional logistic regression modeling was used to calculate odds ratios (ORs) for cancer incidence associated with IGF-related molecules.</p><p><strong>Results: </strong>This analysis included 176 cases and 524 controls. No IGF-related molecules appeared associated with risks of overall or left-sided CRC. Both total IGFBP3 and free IGFBP3 (estimated as IGFBP3 - [IGF1 + IGF2]) were associated with incidence of right-sided CRC (p for trends = 0.027 and 0.003, respectively), with the third tertile of total and free IGFBP3 showing the highest risk (OR = 6.25 and 7.96, respectively). Free IGF, estimated as (IGF1 + IGF2)/IGFBP3, was inversely associated with incidence of right-sided CRC (p for trends = 0.014), with the third tertile showing the lowest risk (OR = 0.18). Among subjects followed for over 3 years, the association of IGF-related molecules with overall CRC was similar. Free IGFBP3 was associated with the incidence of right-sided CRC (p for trends = 0.004). Free IGF was inversely associated with the incidence of right-sided CRC (p for trends = 0.002). However, free IGFs were associated with a risk of left-sided CRC (p for trends = 0.041), with the third tertile showing the highest risk (OR = 3.10).</p><p><strong>Conclusions: </strong>Serum IGF-related molecules are associated with the risk of CRC. These associations might differ by tumor location.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which of Vonoprazan Alone or Intravenous Proton Pump Inhibitor Followed by Vonoprazan Is Optimal for Reducing Delayed Bleeding in Gastric Endoscopic Submucosal Dissection? 单用伏诺哌嗪或静脉注射质子泵抑制剂后再用伏诺哌嗪,哪一种对减少胃内镜下粘膜下剥离的迟发性出血效果最佳?
IF 3 3区 医学
Digestion Pub Date : 2025-03-25 DOI: 10.1159/000545253
Hiroko Abe, Kunio Tarasawa, Waku Hatta, Naotaro Tanno, Yutaka Hatayama, Yohei Ogata, Masahiro Saito, Xiaoyi Jin, Tomoyuki Koike, Akira Imatani, Shin Hamada, Kenji Fujimori, Kiyohide Fushimi, Atsushi Masamune
{"title":"Which of Vonoprazan Alone or Intravenous Proton Pump Inhibitor Followed by Vonoprazan Is Optimal for Reducing Delayed Bleeding in Gastric Endoscopic Submucosal Dissection?","authors":"Hiroko Abe, Kunio Tarasawa, Waku Hatta, Naotaro Tanno, Yutaka Hatayama, Yohei Ogata, Masahiro Saito, Xiaoyi Jin, Tomoyuki Koike, Akira Imatani, Shin Hamada, Kenji Fujimori, Kiyohide Fushimi, Atsushi Masamune","doi":"10.1159/000545253","DOIUrl":"10.1159/000545253","url":null,"abstract":"<p><strong>Introduction: </strong>In gastric endoscopic submucosal dissection (ESD), both vonoprazan alone and intravenous proton pump inhibitor (PPI) followed by vonoprazan have lower delayed bleeding risk than PPI alone. This study aimed to clarify an optimal acid-suppressive method in gastric ESD.</p><p><strong>Methods: </strong>This population-based cohort study included patients who underwent gastric ESD on only vonoprazan (vonoprazan alone group) or intravenous PPI followed by vonoprazan (intravenous PPI group) using the Diagnosis Procedure Combination database in Japan between 2014 and 2021. The primary outcome was delayed bleeding. To balance the two comparison groups, propensity score matching (PSM), based on 18 variables, was performed; subsequently, to compare the bleeding outcome, logistic regression analysis was performed.</p><p><strong>Results: </strong>Of 63,952 patients, 24,710 pairs were compared following PSM. The delayed bleeding risk in the vonoprazan alone group was similar to that in the intravenous PPI group (odds ratio [OR], 1.00; 95% confidence interval, 0.93-1.08; delayed bleeding rate, 5.9% vs. 5.9%). The results were consistent in some sensitivity and subgroup analyses; however, the result was modified by the status of antithrombotic agents (p for interaction = 0.029). In additional analyses, in patients with antithrombotic agent, the vonoprazan alone group had a higher delayed bleeding risk than the intravenous PPI group (OR, 1.15).</p><p><strong>Conclusion: </strong>Both vonoprazan alone and intravenous PPI followed by vonoprazan might be acceptable in gastric ESD when antithrombotic agents were not administered, whereas intravenous PPI followed by vonoprazan might be favorable in patients with antithrombotic agents.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is the Helicobacter pylori Stool Antigen Test with the Bioluminescent Enzyme Immunoassay Affected by Proton Pump Inhibitors? 幽门螺杆菌粪便抗原检测与生物发光酶免疫分析法是否受质子泵抑制剂的影响?
IF 3 3区 医学
Digestion Pub Date : 2025-03-21 DOI: 10.1159/000545347
Chika Kusano, Koshiro Tsutsumi, Toshiki Horii, Sho Suzuki, Hirofumi Kiyokawa, Tadateru Maehata, Itsuko Hirayama, Shinya Minami, Tetsuya Sumiyoshi, Ryuji Nagahama
{"title":"Is the Helicobacter pylori Stool Antigen Test with the Bioluminescent Enzyme Immunoassay Affected by Proton Pump Inhibitors?","authors":"Chika Kusano, Koshiro Tsutsumi, Toshiki Horii, Sho Suzuki, Hirofumi Kiyokawa, Tadateru Maehata, Itsuko Hirayama, Shinya Minami, Tetsuya Sumiyoshi, Ryuji Nagahama","doi":"10.1159/000545347","DOIUrl":"10.1159/000545347","url":null,"abstract":"<p><strong>Introduction: </strong>Proton pump inhibitors (PPIs) can lead to false-negative results in Helicobacter pylori stool antigen (HpSA) testing. A new bioluminescent enzyme immunoassay (BLEIA)-based HpSA test was introduced. This study aimed to evaluate the sensitivity of this test in patients on PPIs and compare its sensitivity with that of the enzyme immunoassay (EIA).</p><p><strong>Methods: </strong>We included patients without a history of H. pylori eradication who were diagnosed as H. pylori-positive via culture, microscopy, rapid urease tests, urea breath tests, serum H. pylori antibody tests, or HpSA tests. The sensitivity of HpSA detection was compared among patients based on their PPI intake using both BLEIA and conventional EIA.</p><p><strong>Results: </strong>Enrollment occurred from December 2020 to July 2022 across 10 facilities, with 109 patients enrolled in both the PPI and non-PPI groups. The sensitivity of BLEIA was 65.9% in the PPI group and 87.1% in the non-PPI group, showing a difference of -22.0% (95% CI: -11.0% to -32.9%) (p = 0.0003). For EIA, the sensitivity was 54.1% in the PPI group and 72.4% in the non-PPI group, with a difference of -18.3% (95% CI: -5.5% to -30.4%) (p = 0.0076). Significant differences in sensitivity were observed for both BLEIA and EIA between the PPI and non-PPI groups (p = 0.005 and p < 0.0001, respectively), with BLEIA demonstrating higher sensitivity.</p><p><strong>Conclusion: </strong>This study indicated that the sensitivity of HpSA detection using BLEIA decreased under PPI administration. Additionally, BLEIA may have higher sensitivity than EIA.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Akkermansia muciniphila and Its Extracellular Vesicles Affect Endocannabinoid System in in vitro Model. 嗜粘杆菌及其胞外囊泡对体外模型内源性大麻素系统的影响
IF 3 3区 医学
Digestion Pub Date : 2025-03-13 DOI: 10.1159/000543446
Pegah Noori, Fattah Sotoodehnejadnematalahi, Pooneh Rahimi, Seyed Davar Siadat
{"title":"Akkermansia muciniphila and Its Extracellular Vesicles Affect Endocannabinoid System in in vitro Model.","authors":"Pegah Noori, Fattah Sotoodehnejadnematalahi, Pooneh Rahimi, Seyed Davar Siadat","doi":"10.1159/000543446","DOIUrl":"https://doi.org/10.1159/000543446","url":null,"abstract":"<p><strong>Introduction: </strong>Recent studies indicate that the gut microbiota controls the host's immune system. Probiotics use different signaling pathways to regulate intestinal permeability, barrier integrity, and energy balance.</p><p><strong>Methods: </strong>This research examined how Akkermansia muciniphila and its extracellular vesicles (EVs) impact inflammation and genes related to the endocannabinoid system in the STC-1 cell line through RT-PCR and ELISA assays.</p><p><strong>Results: </strong>The study's results indicated that EVs had a significant impact on GLP-1 expression compared to the multiplicity of infections (MOI) ratio. Notably, there was a substantial increase in the expression of PYY and GLP-1 genes across all treatments (p < 0.05). Conversely, the expression of CB-1, CB-2, and FAAH genes notably decreased in the STC-1 cell line when treated with MOI 50 of A. muciniphila and an EV concentration of 100 μg/mL (p < 0.05). Both MOI 50 of A. muciniphila and an EV concentration of 100 μg/mL significantly enhanced the expression of the TLR-2 gene. In contrast, EVs at a concentration of 100 μg/mL substantially reduced TLR-4 gene expression. A. muciniphila-derived EVs notably decreased the levels of inflammatory cytokines (TNF-α and IL-6), while increasing IL-10 expression at MOI 100 and an EV concentration of 100 μg/mL. These findings suggest that A. muciniphila and its EVs could regulate the expression of specific genes, serving as targets for maintaining host energy balance.</p><p><strong>Conclusions: </strong>In summary, this study illustrates that A. muciniphila-derived EVs exhibit anti-inflammatory properties and have the potential to modulate gene expression in cases of obesity and gastrointestinal tract inflammation.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Annual Trends in the Diagnosis of Autoimmune Gastritis over 11 Years at a Single Facility in Japan. 日本一家医院11年来自身免疫性胃炎诊断的年度趋势
IF 3 3区 医学
Digestion Pub Date : 2025-03-07 DOI: 10.1159/000544812
Kaoru Nakano, Toshiaki Hirasawa, Ayaka Takasu, Yuka Higashi, Souya Nunobe, Masayuki Shimoda, Kengo Takeuchi, Hiroshi Kawachi
{"title":"Annual Trends in the Diagnosis of Autoimmune Gastritis over 11 Years at a Single Facility in Japan.","authors":"Kaoru Nakano, Toshiaki Hirasawa, Ayaka Takasu, Yuka Higashi, Souya Nunobe, Masayuki Shimoda, Kengo Takeuchi, Hiroshi Kawachi","doi":"10.1159/000544812","DOIUrl":"10.1159/000544812","url":null,"abstract":"<p><strong>Introduction: </strong>Autoimmune gastritis (AIG), a type of chronic atrophic gastritis, is characterized by positive anti-parietal cell antibodies and mucosal atrophy predominantly in the corpus. In Japan, AIG has garnered increasing attention owing to the recent decline in Helicobacter pylori (HP) infection rates, leading to the proposal of diagnostic criteria. These criteria encompass serological test results, endoscopic findings, and histological findings, emphasizing the need for collaboration between endoscopists and pathologists to make an accurate diagnosis. In the present study, we aimed to clarify the annual number of patients with AIG diagnosed over the past 11 years and analyze their endoscopic and histological characteristics.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with AIG newly diagnosed at our institution between 2013 and 2023. Patients were categorized into the \"prior endoscopically diagnosed group\" (ED group) and the \"prior pathologically diagnosed group\" (PD group). The annual trend in AIG diagnosis was analyzed, and clinicopathological characteristics were compared between the groups.</p><p><strong>Results: </strong>In total, 118 patients were diagnosed with AIG during the study period. The number of diagnoses increased after 2018, when a focused effort to identify AIG began, peaking in 2021 with 32 cases. All patients diagnosed before 2018 belonged to the ED group, but subsequent years saw increases in both groups of patients. The PD group had significantly more cases of coexisting gastric carcinoma (86.3% vs. 26.9%, p < 0.001) or HP-associated gastritis (72.4% vs. 32.8%, p = 0.002) than the ED group, whereas the ED group frequently exhibited typical endoscopic findings, such as atrophic gastritis predominantly in the corpus and adherent mucus.</p><p><strong>Conclusion: </strong>Accurate diagnosis of AIG requires familiarity with the diagnostic criteria by endoscopists and pathologists. In cases complicated by gastric carcinoma or HP-associated gastritis, endoscopic findings alone may not suffice for diagnosis, underscoring the critical role of pathologists in interpreting histological findings.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Weakly Supervised Deep Learning Can Analyze Focal Liver Lesions in Contrast-Enhanced Ultrasound. 弱监督深度学习可以分析对比增强超声的局灶性肝脏病变。
IF 3 3区 医学
Digestion Pub Date : 2025-03-06 DOI: 10.1159/000545098
Adil Oezsoy, James Alexander Brooks, Marko van Treeck, Yvonne Doerffel, Ulrike Morgera, Jens Berger, Marco Gustav, Oliver Lester Saldanha, Tom Luedde, Jakob Nikolas Kather, Tobias Paul Seraphin, Michael Kallenbach
{"title":"Weakly Supervised Deep Learning Can Analyze Focal Liver Lesions in Contrast-Enhanced Ultrasound.","authors":"Adil Oezsoy, James Alexander Brooks, Marko van Treeck, Yvonne Doerffel, Ulrike Morgera, Jens Berger, Marco Gustav, Oliver Lester Saldanha, Tom Luedde, Jakob Nikolas Kather, Tobias Paul Seraphin, Michael Kallenbach","doi":"10.1159/000545098","DOIUrl":"10.1159/000545098","url":null,"abstract":"<p><strong>Introduction: </strong>Assessing the malignancy of focal liver lesions (FLLs) is an important yet challenging aspect of routine patient care. Contrast-enhanced ultrasound (CEUS) has proved to be a highly reliable tool but is very dependent on the examiner's expertise. The emergence of artificial intelligence has opened doors to algorithms that could potentially aid in the diagnostic process. In this study, we evaluate the performance of a weakly supervised deep learning model in classifying FLLs as malignant or benign.</p><p><strong>Methods: </strong>Our retrospective feasibility study was based on a cohort of patients from a tertiary care hospital in Germany undergoing routine CEUS examination to evaluate malignancy of FLL. We trained a weakly supervised attention-based multiple instance learning algorithm during 5-fold cross-validation to distinguish malignant from benign liver tumors, without using any manual annotations, only case labels. We aggregated the on-average best performing cross-validation cycle and tested this combined model on a held-out test set. We evaluated its performance using standard performance metrics and developed explainability methods to gain insight into the model's decisions.</p><p><strong>Results: </strong>We enrolled 370 patients, comprising a total of 955,938 images extracted from CEUS videos or manually captured during the examination. Our combined model was able to identify malignant lesions with a mean area under the receiver operating curve of 0.844 in the cross-validation experiment and 0.94 (95% CI: 0.89-0.99) in the held-out test set. The accuracy, sensitivity, specificity, and F1-Score of the combined model in finding malignant lesions in the held-out test, yielded 80.0%, 81.8%, 84.6%, and 0.81, respectively. Our exploratory analysis using visual explainability methods revealed that the model appears to prioritize information that is also highly relevant to expert clinicians in this task.</p><p><strong>Conclusion: </strong>Weakly supervised deep learning can classify malignancy in CEUS examinations of FLLs and thus might one day be able to assist doctors' decision-making in clinical routine.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Xiayuxue Decoction Plays an Antidevelopment Role in Hepatocellular Carcinoma through Intestinal-Hepatic Axis. 下瘀血汤通过肠-肝轴作用于肝细胞癌。
IF 3 3区 医学
Digestion Pub Date : 2025-02-25 DOI: 10.1159/000543834
Ting Zhou, Liyuan Pei, Ya Chen, Xuejing Wang, Hongyu Fang, Xiaoyan Zeng, Xuefei Tian
{"title":"Xiayuxue Decoction Plays an Antidevelopment Role in Hepatocellular Carcinoma through Intestinal-Hepatic Axis.","authors":"Ting Zhou, Liyuan Pei, Ya Chen, Xuejing Wang, Hongyu Fang, Xiaoyan Zeng, Xuefei Tian","doi":"10.1159/000543834","DOIUrl":"10.1159/000543834","url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, the effect of \"intestinal-hepatic axis\" in tumorigenesis of hepatocellular carcinoma (HCC) has been paid more and more attention, and the imbalance of gut microbiota is closely related to the pathogenesis of HCC. The Xiayuxue decoction (XYXD) has inhibitory effect on hepatic fibrosis, but the effect of XYXD on HCC is not clear.</p><p><strong>Methods: </strong>We induced HCC mouse model by diethylnitrosamine and CCL4. HCC mice were treated with XYXD gavage. Hematoxylin-eosin staining was used to detect the pathological changes of liver tissue in mice. Immunohistochemistry was used to detect the level of Ki-67 in liver tumor and ZO-1 in colon tissue. The level of inflammatory factors in plasma, liver, and colon tissue of mice was detected by ELISA. The changes of macrophages and neutrophils in colorectal tissues of mice were counted by immunofluorescence. 16S sequencing was used to analyze the effect of XYXD treatment on gut microbiota of HCC mice.</p><p><strong>Results: </strong>Our study found that XYXD could inhibit the progress of HCC. XYXD upregulated the expression levels of ZO-1, occludin, and claudin in colon tissue to repair intestinal mucosal barrier. XYXD could alleviate the infiltration of intestinal immune cells in HCC mice by inhibiting the data of macrophages and neutrophils in colon tissue and downregulating SIgA level. XYXD also regulated the composition of intestinal microorganisms and improved the diversity of gut microbiota, thus affecting the progress of HCC.</p><p><strong>Conclusion: </strong>XYXD inhibits the progress of HCC by influencing gut microbiota to regulate intestinal and liver inflammation and intestinal immune response.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信